JPH03224463A - Nutrient composition - Google Patents
Nutrient compositionInfo
- Publication number
- JPH03224463A JPH03224463A JP2324762A JP32476290A JPH03224463A JP H03224463 A JPH03224463 A JP H03224463A JP 2324762 A JP2324762 A JP 2324762A JP 32476290 A JP32476290 A JP 32476290A JP H03224463 A JPH03224463 A JP H03224463A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- oil
- nutritional composition
- potato protein
- fats
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 235000015097 nutrients Nutrition 0.000 title description 2
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 29
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 29
- 239000003921 oil Substances 0.000 claims abstract description 23
- 239000003925 fat Substances 0.000 claims abstract description 20
- 235000019197 fats Nutrition 0.000 claims abstract description 20
- 244000061456 Solanum tuberosum Species 0.000 claims abstract description 19
- 235000002595 Solanum tuberosum Nutrition 0.000 claims abstract description 19
- 230000002255 enzymatic effect Effects 0.000 claims abstract description 13
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 8
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 8
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims abstract description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 4
- 235000020778 linoleic acid Nutrition 0.000 claims abstract description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 4
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 3
- 239000000194 fatty acid Substances 0.000 claims abstract description 3
- 229930195729 fatty acid Natural products 0.000 claims abstract description 3
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 3
- 235000016709 nutrition Nutrition 0.000 claims description 30
- 150000002632 lipids Chemical class 0.000 abstract description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 8
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 241001601725 Sthenias Species 0.000 abstract 1
- 210000001772 blood platelet Anatomy 0.000 abstract 1
- 229960004232 linoleic acid Drugs 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 34
- 235000018102 proteins Nutrition 0.000 description 25
- 235000019198 oils Nutrition 0.000 description 18
- 210000002381 plasma Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 235000012000 cholesterol Nutrition 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 108010073771 Soybean Proteins Proteins 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 7
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 102000011632 Caseins Human genes 0.000 description 6
- 108010076119 Caseins Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000005018 casein Substances 0.000 description 6
- 235000021240 caseins Nutrition 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 235000019710 soybean protein Nutrition 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 235000019485 Safflower oil Nutrition 0.000 description 3
- 230000000702 anti-platelet effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000005713 safflower oil Nutrition 0.000 description 3
- 239000003813 safflower oil Substances 0.000 description 3
- 229940001941 soy protein Drugs 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 2
- 241001517013 Calidris pugnax Species 0.000 description 2
- 235000019743 Choline chloride Nutrition 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000021120 animal protein Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229960003178 choline chloride Drugs 0.000 description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 210000001321 subclavian vein Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241001062872 Cleyera japonica Species 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229940067131 aspirin 100 mg Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000021048 nutrient requirements Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【発明の詳細な説明】
産1」J■U1走証
本発明は、栄養組成物に関し、さらに詳しくはポテトタ
ンパク質またはその酵素的加水分解物にα−リノレン酸
とリノール酸を高含有する油脂を配合した栄養組成物に
関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a nutritional composition, and more specifically, to potato protein or its enzymatic hydrolyzate, fat and oil containing a high content of α-linolenic acid and linoleic acid. The present invention relates to a formulated nutritional composition.
皿来坐肢止
従来、経腸ならびに経口的に栄養補給するために使用さ
れている栄養組成物の窒素源としては、結晶アミノ酸の
他には、カゼインをはじめとする動物性タンパク賞もし
くはその酵素的加水分解物が用いられている。しかしな
がら、動物性タンパク賞とその酵素的加水分解物は、栄
養価では優れているものの、血漿脂質を上昇させる作用
が一般的に認められること(Caroll、 K、に、
Dietaryprotein in relati
on to plasma choiesteroll
evels and atherosclerosis
、 Nutr、 Rev、 34:1−5; 197
B)から、脂質代謝改善作用という薬効的効果を意図し
た栄養組成物の窒素源としては、植物性タンパク質の中
では比較的栄養価の高い大豆タンパク質またはその酵素
的加水分解物が利用されている。上記栄養組成物の窒素
源として結晶アミノ酸を使用した際に問題となる安定性
や溶解性といった製剤学的欠点は、タンパク質の酵素的
加水分解物を用いることによって解決され、栄養学的に
も同等以上の有効性が既に特開昭64−20060号で
提案されている。臨床では、動脈硬化の一次子防の観点
から血漿脂質レベルが危険因子として重要視されている
( The Lipid Re5earch C11n
icsCoronary Primary Preve
ntion Trial Re5ults :1、
Il、 JAMA%江: 351−374.1984
)。一方、脳梗塞や心筋梗塞等の血栓性疾患において血
小板機能の亢進が報告(丸山征朗:脳梗塞と血液凝固。Nitrogen sources for nutritional compositions conventionally used for enteral and oral nutritional supplementation include crystalline amino acids, as well as animal proteins such as casein or their enzymes. hydrolyzate is used. However, although animal proteins and their enzymatic hydrolysates have excellent nutritional value, they are generally recognized to have the effect of increasing plasma lipids (Carroll, K.,
Dietary protein in relative
on to plasma choiesterroll
evel and atherosclerosis
, Nutr, Rev, 34:1-5; 197
From B), soybean protein or its enzymatic hydrolyzate, which has relatively high nutritional value among vegetable proteins, is used as a nitrogen source for nutritional compositions intended for the medicinal effect of improving lipid metabolism. . The pharmaceutical disadvantages such as stability and solubility that arise when crystalline amino acids are used as nitrogen sources in the above nutritional compositions can be solved by using enzymatic protein hydrolysates, which are nutritionally equivalent. The above effectiveness has already been proposed in Japanese Patent Laid-Open No. 64-20060. In clinical practice, plasma lipid levels are considered important as a risk factor from the perspective of primary prevention of arteriosclerosis (The Lipid Research C11n
icsCoronary Primary Preve
tion Trial Results: 1,
Il, JAMA%E: 351-374.1984
). On the other hand, it has been reported that platelet function is enhanced in thrombotic diseases such as cerebral infarction and myocardial infarction (Seiro Maruyama: Cerebral infarction and blood coagulation.
日本医師会識語、 88.352−360; 1982
)されており、これらの疾患の再発予防の薬物療法とし
て一般的にアスピリンやチクロピジン等の抗血小板薬が
用いられている(塩 栄夫:再発予防、 Pro、 M
ed。Japanese Medical Association Knowledge, 88.352-360; 1982
), and antiplatelet drugs such as aspirin and ticlopidine are generally used as drug therapy to prevent recurrence of these diseases (Hideo Shio: Relapse Prevention, Pro, M
ed.
旦、 1109−1112; 1988)。Dan, 1109-1112; 1988).
我々は栄養素材の中で、血漿脂質の上昇抑制作用を有す
る植物性タンパク質に注目し、その血小板機能に及ぼす
作用をラットにコレステロール食を与えて検討した結果
、大豆タンパク質には血漿脂質上昇抑制作用は認められ
たが、血小板に対してはコラゲン凝集を明らかに亢進し
た。従って、大豆タンパン質は血栓の形成を助長する可
能性があり、大豆タンパク質またはその酵素的加水分解
物を含む栄養組成物に血栓性の疾患を予防する薬効的効
果は期待できない。Among nutritional materials, we focused on vegetable protein, which has the effect of suppressing the rise in plasma lipids, and investigated its effect on platelet function by feeding rats with a cholesterol diet. However, collagen aggregation was clearly enhanced for platelets. Therefore, soy protein may promote the formation of blood clots, and a nutritional composition containing soy protein or its enzymatic hydrolyzate cannot be expected to have a medicinal effect on preventing thrombotic diseases.
本主肌■課国
本発明の課題は、優れた抗血小板作用と脂質低下作用を
有し、血栓性の疾患に対する予防および治療に有効な栄
養組成物を提供することにある。An object of the present invention is to provide a nutritional composition that has excellent antiplatelet and lipid-lowering effects and is effective in the prevention and treatment of thrombotic diseases.
i ゛′するための
本発明者らはかかる課題を解決すべく、種々の研究の結
果、ポテトタンパク質および/またはその酵素的加水分
解物と、−榊す油脂とを含有する組成物が、優れた抗血
小板作用と血漿脂質低下作用を有することを見いだし、
本発明を完成するに到った。In order to solve this problem, the present inventors have conducted various studies and found that a composition containing potato protein and/or its enzymatic hydrolyzate and - Sakaki oil and fat is excellent. found that it has antiplatelet and plasma lipid-lowering effects.
The present invention has now been completed.
ポテトタンパク質およびその酵素的加水分解物は他の植
物性タンパク質と同様、血漿脂質上昇抑制作用を有して
いる上に、血小板凝集の亢進を抑制する作用をも併せも
つ有用なタンパク素材である。これと油脂を組み合わせ
ることにより、血漿脂質上昇と血小板凝集の亢進を著し
く抑制することができる。Potato protein and its enzymatic hydrolyzate, like other vegetable proteins, are useful protein materials that not only have the effect of suppressing the increase in plasma lipids, but also the effect of suppressing the promotion of platelet aggregation. By combining this with fats and oils, increases in plasma lipids and acceleration of platelet aggregation can be significantly suppressed.
本発明で使用するポテトタンパク質はデンプン精製工程
でポテトからデンプンを取り去った後に分離、濃縮、乾
燥することにより製造されており、主として飼料用タン
パク質の原料として用いられている。ポテトタンパク質
は酵素的に加水分解することによって消化吸収性と栄養
価を高め、同時に溶解性と色と食感を改善することがで
き(特開昭64−20060号)、栄養組成物の窒素源
として利用し易くすることができる。本発明の栄養組成
物においては、ポテトタンパク質またはその酵素的加水
分解物を、単独もしくは組み合わせて使用することがで
きる。ポテトタンパク質およびその酵素的加水分解物は
、成人の蛋白質所要量を充足する点から、10〜30重
量%含有することが望ましい。The potato protein used in the present invention is produced by removing starch from potatoes in a starch purification process, followed by separation, concentration, and drying, and is mainly used as a raw material for protein for feed. By enzymatically hydrolyzing potato protein, it can increase digestibility and nutritional value, and at the same time improve solubility, color, and texture (Japanese Patent Application Laid-Open No. 64-20060), and it can be used as a nitrogen source for nutritional compositions. It can be easily used as In the nutritional composition of the present invention, potato protein or its enzymatic hydrolyzate can be used alone or in combination. Potato protein and its enzymatic hydrolyzate are preferably contained in an amount of 10 to 30% by weight in order to satisfy the protein requirements for adults.
油脂としては、脂肪酸成分としてα−リノレン酸とリノ
ール酸を高含有する油脂が適しており、栄養組成物中に
油脂を5〜20重量%含有することが成人の栄養所要量
を充足する点からも望ましい。本発明で使用する油脂と
しては大豆油、サフラワー油、しそ油、コーン油、小麦
胚芽油、採種油、月見草油等を挙げることができる。こ
れらの油脂を単独または組み合わせて使用することがで
きる。As the fat and oil, fats and oils that contain a high content of α-linolenic acid and linoleic acid as fatty acid components are suitable, and from the viewpoint that containing 5 to 20% by weight of fats and oils in the nutritional composition satisfies the nutritional requirements of adults. is also desirable. Examples of the oils and fats used in the present invention include soybean oil, safflower oil, perilla oil, corn oil, wheat germ oil, seed oil, and evening primrose oil. These fats and oils can be used alone or in combination.
本発明の栄養組成物は、例えば表1に示すような組成を
有する。The nutritional composition of the present invention has a composition as shown in Table 1, for example.
表
■
栄養所要量と本発明の栄養組成
エネ11キー (Kcal)
タンパク質(g)
油 脂軸)
糖 質(g)
250
5
(20χ)
600
4
250
5
0
13
ビタミン 八(ug**本)
B+ (mg)
Bz (mg)
B6 (mg)
B I Z (ug)
C(mg)
D(ug本本本)
E(mg本本*)
に (ug)
ナイアシン (B)
葉酸(mg)
パントテン 酸(mg)
ビオチン(ug)
コリン (mg)
イノシトール (mg)
40
0.6
0.8
0
2.5
7 ・・・
O
00
■
1.2
2.2
0
70〜140
3
0.4
4〜7
100〜200
(mg)
(1g)
(mg)
(ug)
(mg)
(mg)
(mg)
(mg)
(mg)
(爾g)
(ug)
00
00
300 ・・・
0
1.6〜3.2
5
100〜
800 750
800 750
300 375
1100〜3300 1100
1875〜5625 1875
1700〜5100 1700
10 13
2.5〜5゜02.5
2.0〜3.02
15 19
150 125
(mg)
(mg)
(B)
(mg)
1.5〜4゜01.5
0.05〜0.2 0.05
0.05〜0.2 0,05
0.15〜0.5 0.15
「日本人の栄養所要量」 (昭和59年)生活活動強度
I:女80歳以上
Recommended dietary allow
ances(1980) :女76歳以上
lug RE=3.33 V、A、(Ill)lug
コレカルシフxU−ル=40 V、D、(10)l
a+g cr−)ニア7zll−3=1.5 V、
E、(10)第四次改訂
本発明の栄養組成物は、栄養素として経口または経腸的
に、「日本人の栄養所要量」 (昭和59年)に従って
一日1回〜数回に分けて摂取される。Table ■ Nutrient requirements and nutritional composition of the present invention Energy 11 keys (Kcal) Protein (g) Oil (fat axis) Carbohydrate (g) 250 5 (20χ) 600 4 250 5 0 13 Vitamin 8 (ug** books) B+ (mg) Bz (mg) B6 (mg) B I Z (ug) C (mg) D (ug book book) E (mg book book *) Niacin (B) Folic acid (mg) Pantothenic acid (mg) Biotin (ug) Choline (mg) Inositol (mg) 40 0.6 0.8 0 2.5 7 ... O 00 ■ 1.2 2.2 0 70-140 3 0.4 4-7 100-200 (mg) (1g) (mg) (ug) (mg) (mg) (mg) (mg) (mg) (erg) (ug) 00 00 300 ... 0 1.6-3.2 5 100 ~ 800 750 800 750 300 375 1100~3300 1100 1875~5625 1875 1700~5100 1700 10 13 2.5~5°02.5 2.0~3.02 15 19 150 125 (mg) (mg) ( B) (mg) 1.5~4゜01.5 0.05~0.2 0.05 0.05~0.2 0.05 0.15~0.5 0.15 "Nutrition requirements for Japanese people" (1981) Life activity intensity I: Female 80 years of age or older Recommended diet allowance
ances (1980): Female 76 years old or older lug RE=3.33 V, A, (Ill) lug
Cholecalcif xU-L = 40 V, D, (10)l
a+g cr-) near 7zll-3=1.5 V,
E. (10) Fourth Revision The nutritional composition of the present invention can be administered orally or enterally as nutrients, once to several times a day in accordance with the "Nutritional Requirements for Japanese People" (1981). Ingested.
本発明の栄養組成物は、優れた抗血小板作用と脂質低下
作用を併せ持つことから、動脈硬化や血栓性疾患の予防
や治療に有用であり、心筋梗塞や脳卒中の栄養補給に適
しており、中でも脳梗塞の再発予防に有用である。Since the nutritional composition of the present invention has both excellent antiplatelet and lipid-lowering effects, it is useful for the prevention and treatment of arteriosclerosis and thrombotic diseases, and is suitable for nutritional support for myocardial infarction and stroke, among others. It is useful for preventing recurrence of cerebral infarction.
実見困 以下、実施例により本発明をより具体的に説明する。Really difficult to see Hereinafter, the present invention will be explained in more detail with reference to Examples.
実施例1
5週齢のSD系雄性ラットに0.5%コレステロール食
を供与し、8週目に鎖骨上静脈より採血し、酵素法にて
血漿コレステロール濃度を測定し、9週目に24時間絶
食の後、動脈血より調製したPRP (多血小板血漿)
を用いて血小板凝集能をアブリボメーター(NBSへマ
ドレーサー801)で測定した。実験食の組成(%)は
、タンパク質20、ミネラル混合4、ビタミン混合l、
塩化コリン0.15、セルロース2、コーン油5、コレ
ステロール0.5、コーン酸ナトリウム0.125 、
シュクロースで100に調整した。タンパク質としては
、カゼイン、大豆タンパク質、ポテトタンパク質をそれ
ぞれ使用した。コレステロールを含まないカゼイン群を
コントロールとした。Example 1 A 0.5% cholesterol diet was fed to 5-week-old SD male rats. At the 8th week, blood was collected from the supraclavicular vein, and the plasma cholesterol concentration was measured by an enzymatic method. At the 9th week, blood was collected for 24 hours. PRP (platelet rich plasma) prepared from arterial blood after fasting
Platelet aggregation ability was measured with an alibometer (NBS Hemaderacer 801). The composition (%) of the experimental food was: protein 20, mineral mixture 4, vitamin mixture 1,
Choline chloride 0.15, cellulose 2, corn oil 5, cholesterol 0.5, sodium conate 0.125,
Adjusted to 100 with sucrose. Casein, soybean protein, and potato protein were used as proteins. A casein group containing no cholesterol was used as a control.
血漿コレステロール濃度は、カゼイン群でコントロール
に比べ有意な上昇が認められたが、植物性タンパク質で
ある大豆タンパク質、ポテトタンパク質群では血米コレ
ステロールの上昇が抑制されていた(表2)。Although a significant increase in plasma cholesterol concentration was observed in the casein group compared to the control, the increase in blood rice cholesterol was suppressed in the soybean protein and potato protein groups, which are vegetable proteins (Table 2).
表 2 血漿コレステロール濃度
カゼイン
大豆タンパク
ポテトタンパク
コントロール
mg/10抛β
9 138±23$
1091±12
10 105±27
9 94±14
血小板凝集は、コラゲンを凝集惹起物質とした場合、最
大凝集率で大豆タンパク質群がコントロールの約2倍に
亢進していたのに対して、ポテトタンパク群では明らか
に凝集の亢進が抑制されていた(表3)。Table 2 Plasma cholesterol concentration Casein Soy protein Potato protein Control mg/10 抛β 9 138 ± 23 $ 1091 ± 12 10 105 ± 27 9 94 ± 14 In the protein group, the aggregation was approximately twice as high as in the control, whereas in the potato protein group, the aggregation was clearly suppressed (Table 3).
表 3 最大凝集率(%)
カゼイン 8 4±2 53±7大豆タンパク
9 8±9 60±6本ポテトタンパク 9 7
±6 48±15コントロール 8 6±2 32±
18実施例2
実施例1と同様に、5週齢のSD系雌雄性ラット0.5
%コレステロール食を供与し、2週毎に鎖骨下静脈より
採血して血漿コレステロール濃度を、8週目に血小板凝
集能を測定した。実験食の組成(%)は、タンパク質2
0、ミネラル混合4、ビタミン混合11塩化コリン0.
15、セルロース2、油脂5、コレステロール0.5、
コール酸ナトリウム0.125 、シュクロースで10
0に言周整した。タンパク質にカゼインを、油脂にサフ
ラワー油を配合した実験食を対照群、タンパク質にポテ
トタンパク酵素分解物を、油脂にサフラワー油を配合し
た実験食をペプチド群、タンパク質にカゼインを、油脂
に小麦胚芽油としそ油のブレンド油を配合した実験食を
ブレンド油脂、タンパク質にポテトタンパク酵素分解物
を、油脂にブレンド油を配合した実験食をペプチド+ブ
レンド油脂、対照群と同じ実験食に剖検3日前からアス
ピリン100mg/kg/dayを連設したものをアス
ピリン群とした。Table 3 Maximum aggregation rate (%) Casein 8 4±2 53±7 Soybean protein
9 8±9 60±6 potato protein 9 7
±6 48±15 control 8 6±2 32±
18 Example 2 Same as Example 1, 5 week old male and female SD rats with 0.5
% cholesterol diet, blood was collected from the subclavian vein every two weeks to measure plasma cholesterol concentration, and platelet aggregation ability was measured at 8 weeks. The composition of the experimental food (%) is protein 2
0, mineral mixture 4, vitamin mixture 11 choline chloride 0.
15, cellulose 2, fats and oils 5, cholesterol 0.5,
Sodium cholate 0.125, sucrose 10
I adjusted my wording to 0. The experimental food containing casein as protein and safflower oil as fat was used as the control group, the experimental food containing enzymatically decomposed potato protein as protein and safflower oil as fat was used as the peptide group, the protein was casein and fat was wheat as fat. An experimental food containing a blend of germ oil and soybean oil was used as a blended oil, a protein contained potato protein enzyme decomposition product, and an experimental food containing a blend of oil and fat as peptides and blended oil was used as the control group.Autopsy 3 Those who received aspirin 100 mg/kg/day from the previous day were designated as the aspirin group.
血漿コレステロールはペプチド群、ブレンド油脂で上昇
傾向は認められたものの、対照群に比較して有意に上昇
が抑制されていた。さらに、ペプチド+ブレンド油脂で
は血漿コレステロールの上昇も認められず、ペプチドと
ブレンド油の相加効果が明かであった(図1)。血小板
凝集は、コラゲンを凝集惹起物質とした場合、最大凝集
率でペプチド群、ブレンド油脂が対照群に比較して低値
となる傾向を示したが、ペプチド+ブレンド油脂では有
意に低値となり血小板凝集抑制が認められ、その効果は
アスピリン群と同等であった。(図2)主尻生並来
以上のことから明らかなように、本発明の栄養組成物は
優れた血漿脂質の上昇抑制作用と血小板凝集の先進抑制
作用を併せもち、動豚硬化や血栓性疾患の予防や治療に
有効である。Although plasma cholesterol tended to increase in the peptide group and blended fat and oil, the increase was significantly suppressed compared to the control group. Furthermore, no increase in plasma cholesterol was observed with the peptide + blended oil, and the additive effect of the peptide and blended oil was clear (Figure 1). Regarding platelet aggregation, when collagen was used as the aggregation-inducing substance, the maximum aggregation rate tended to be lower in the peptide group and the blended oil compared to the control group, but the value was significantly lower in the peptide + blended oil and platelet Aggregation inhibition was observed, and the effect was equivalent to that of the aspirin group. (Figure 2) As is clear from the above, the nutritional composition of the present invention has both an excellent effect of suppressing the increase in plasma lipids and an advanced suppressing effect of platelet aggregation, and is effective in preventing animal stiffness and thrombosis. It is effective in preventing and treating diseases.
図1は、実施例2におけるコレステロール上昇抑制作用
を示し、コレステロール添加量を8週間自由摂取させた
ラット(n=9〜10)の鎖骨下静脈から経通的に採血
した血漿中の総コレステロールを測定した結果である。
図2は、実施例2における血小板凝集抑制作用を示し、
コレステロール添加量を8週間自由摂取させたラフ)(
n=6〜8)の多血小板血漿を用いて、コラゲン(20
μg/raβ)による凝集を測定した結果である。Figure 1 shows the inhibitory effect on cholesterol rise in Example 2, and shows the total cholesterol in the plasma of rats (n = 9 to 10), which were given ad libitum supplementary amounts of cholesterol for 8 weeks, and blood was collected transcutaneously from the subclavian vein. These are the measured results. FIG. 2 shows the platelet aggregation inhibitory effect in Example 2,
Ruff (Ruff) (who was given ad libitum supplementary amounts of cholesterol for 8 weeks)
Collagen (20
This is the result of measuring aggregation by μg/raβ).
Claims (6)
分解物と、油脂とを含有することを特徴とする栄養組成
物。(1) A nutritional composition characterized by containing potato protein and/or its enzymatic hydrolyzate and oil and fat.
分解物が10〜30重量%含まれている請求項1記載の
栄養組成物。(2) The nutritional composition according to claim 1, containing 10 to 30% by weight of potato protein and/or its enzymatic hydrolyzate.
リノール酸を高含有するものである請求項1記載の栄養
組成物。(3) The nutritional composition according to claim 1, wherein the oil or fat has a high content of α-linolenic acid and linoleic acid as its fatty acid components.
の栄養組成物。(4) The nutritional composition according to claim 1, which contains 5 to 20% by weight of fats and oils.
成物。(5) The nutritional composition according to claim 1, which is for oral or enteral use.
成物。(6) The nutritional composition according to claim 1, which is for patients with thrombotic diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2324762A JP2932684B2 (en) | 1989-12-29 | 1990-11-27 | Nutritional composition for patients with thrombotic diseases |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1-342211 | 1989-12-29 | ||
| JP34221189 | 1989-12-29 | ||
| JP2324762A JP2932684B2 (en) | 1989-12-29 | 1990-11-27 | Nutritional composition for patients with thrombotic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03224463A true JPH03224463A (en) | 1991-10-03 |
| JP2932684B2 JP2932684B2 (en) | 1999-08-09 |
Family
ID=26571597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2324762A Expired - Lifetime JP2932684B2 (en) | 1989-12-29 | 1990-11-27 | Nutritional composition for patients with thrombotic diseases |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2932684B2 (en) |
-
1990
- 1990-11-27 JP JP2324762A patent/JP2932684B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2932684B2 (en) | 1999-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6436431B1 (en) | Fortified rice bran food product and method for promoting cardiovascular health | |
| JP4699901B2 (en) | Dietary additive with body fat metabolism function and combustion energy utilization function | |
| CA2419026C (en) | Nutritional composition and method for improving protein deposition | |
| ES2202454T3 (en) | USE OF A BALANCING AGENT FOR OMEGA-3 AND OMEGA-6 Unsaturated FATTY ACIDS. | |
| US8388949B2 (en) | Compositions comprising pantothenic acid and their use for stimulating appetite | |
| US20080193561A1 (en) | Preparation for the prevention and/or treatment of vascular disorders | |
| CN104666290A (en) | Composition for ameliorating a reduced higher brain function resulting from organic brain lesions | |
| CA2820229A1 (en) | Cardio-protective agents from kiwifruits | |
| EP0437524B1 (en) | Triglyceride and nutritional composition comprising such triglycerides. | |
| AU2004283610B2 (en) | Composition functioning to prevent or mitigate symptom or disease attributable to blood vessel aging | |
| EP3135281A1 (en) | Composition for preventing or improving peripheral neuropathy | |
| WO2000009138A1 (en) | Nutritional compositions for preventing or treating hyperlipoproteinemia | |
| KR100413940B1 (en) | Preventing or improving medical symptoms caused by delayed allergic reactions | |
| JP3173844B2 (en) | Agent for increasing ω3 fatty acid in living tissue and nutritional composition containing the same | |
| EP3630088B1 (en) | Medium chain fatty acids for use in the prevention or treatment of valvular heart disease | |
| WO2019106626A1 (en) | Composition for oral administration, the use of the composition in prevention and treatment of mucositis, and a method of treatment of mucositis | |
| JP2932684B2 (en) | Nutritional composition for patients with thrombotic diseases | |
| EP0435683A1 (en) | Nutrient composition | |
| US10285967B2 (en) | Monoacylglycerols for use in conjunction with a lipase inhibitor and/or diets low in fat and/or calories | |
| AU2002320118B2 (en) | Fortified ricebran food product and method for promoting cardiovascular health | |
| JPH04279523A (en) | Fatty oil processed product for stimulating immunity | |
| JPWO2000009138A1 (en) | Nutritional composition for preventing or treating hyperlipoproteinemia | |
| JP2011046647A (en) | CHOLESTEROL INHIBITOR CONTAINING POLY-gamma-GLUTAMIC ACID | |
| Ford | Essential fatty acids | |
| AU2002320118A1 (en) | Fortified ricebran food product and method for promoting cardiovascular health |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090528 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090528 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090528 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100528 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100528 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110528 Year of fee payment: 12 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110528 Year of fee payment: 12 |